News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
766,911 Results
Type
Article (63701)
Company Profile (724)
Press Release (702486)
Section
Business (220621)
Career Advice (2904)
Deals (37598)
Drug Delivery (104)
Drug Development (86412)
Employer Resources (177)
FDA (17311)
Job Trends (16526)
News (373240)
Policy (36068)
Tag
Academia (2924)
Alliances (53329)
Alzheimer's disease (1306)
Approvals (17217)
Artificial intelligence (136)
Bankruptcy (371)
Best Places to Work (12445)
Biotechnology (498)
Breast cancer (122)
Cancer (1056)
Career advice (2426)
Cell therapy (239)
Clinical research (68142)
Collaboration (368)
Compensation (189)
COVID-19 (2723)
C-suite (93)
Data (1005)
Diabetes (155)
Diagnostics (6584)
Drug pricing (92)
Earnings (89660)
Employer resources (154)
Events (121020)
Executive appointments (282)
FDA (17804)
Funding (328)
Gene therapy (177)
GLP-1 (652)
Government (4804)
Healthcare (20543)
Infectious disease (2811)
Inflammatory bowel disease (114)
Interviews (503)
IPO (17125)
Job creations (4482)
Job search strategy (2074)
Layoffs (463)
Legal (8769)
Lung cancer (169)
Manufacturing (178)
Medical device (14251)
Medtech (14256)
Mergers & acquisitions (20508)
Metabolic disorders (424)
Neuroscience (1580)
NextGen Class of 2024 (7481)
Non-profit (5038)
Northern California (1373)
Obesity (246)
Opinion (237)
Patents (103)
People (61310)
Pharmaceutical (141)
Phase I (21137)
Phase II (29747)
Phase III (22391)
Pipeline (333)
Postmarket research (3019)
Preclinical (9283)
Radiopharmaceuticals (255)
Rare diseases (216)
Real estate (6891)
Regulatory (23831)
Research institute (2612)
Resumes & cover letters (467)
Southern California (1231)
Startups (4004)
United States (13525)
Vaccines (605)
Weight loss (196)
Date
Today (138)
Last 7 days (991)
Last 30 days (3537)
Last 365 days (37855)
2024 (33612)
2023 (42329)
2022 (53728)
2021 (58534)
2020 (57497)
2019 (50966)
2018 (38641)
2017 (35113)
2016 (35216)
2015 (41391)
2014 (36413)
2013 (33539)
2012 (33479)
2011 (33922)
2010 (32826)
Location
Africa (958)
Arizona (210)
Asia (43428)
Australia (7625)
California (3203)
Canada (1235)
China (244)
Colorado (141)
Connecticut (156)
Europe (99430)
Florida (432)
Georgia (117)
Illinois (377)
Indiana (206)
Kansas (102)
Maryland (598)
Massachusetts (2649)
Michigan (167)
Minnesota (284)
New Jersey (934)
New York (930)
North Carolina (812)
Northern California (1373)
Ohio (139)
Pennsylvania (813)
South America (1350)
Southern California (1231)
Texas (457)
Washington State (378)
766,911 Results for "new england biolabs inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
New England Biolabs® and Inorevia to partner on novel solutions for the preparation of challenging samples for next generation sequencing
New England Biolabs (NEB ®) and Inorevia announce a collaboration to develop automated workflows to maximize data quality by preparation of sequence-ready libraries from challenging samples using NEBNext® library preparation reagents on Inorevia’s Magelia® automation platform.
June 18, 2024
·
4 min read
New England Biolabs® Launches NEBNext® Enzymatic 5hmC-seq Kit, for enzyme-based 5hmC detection at single-base resolution
New England Biolabs (NEB®) today announced the launch of the NEBNext Enzymatic 5hmC-seq Kit (E5hmC-seq™), a novel enzyme-based method for the specific detection of 5hmC sites.
February 13, 2024
·
2 min read
biomodal Files Patent Infringement Lawsuit Against New England Biolabs
July 2, 2024
·
2 min read
Press Releases
BioLab Holdings, Inc. Launches New Triple Layered Amniotic Skin Substitute Product
October 3, 2024
·
2 min read
Drug Development
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine(NEJM) has published results from a positive Phase 3 trial for Dupixent® (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE).
June 26, 2024
·
22 min read
Biotech Beach
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
Oncocyte Corporation, a precision diagnostics company, announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine.
May 30, 2024
·
8 min read
Drug Development
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the primary study results from its CAHtalyst™ Pediatric Phase 3 study investigating crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency have been published in The New England Journal of Medicine online edition and will appear in a future print issue of the journal.
June 3, 2024
·
11 min read
Drug Development
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the primary study results from its CAHtalyst™ Phase 3 study investigating crinecerfont for the treatment of adults ages 18 and older with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency have been published in The New England Journal of Medicine online edition and will appear in a future print issue of the journal.
June 3, 2024
·
11 min read
Drug Development
Vertex Finally Reaches Pricing Deal With England’s NHS for Cystic Fibrosis Drugs
Vertex Pharmaceuticals’ three cystic fibrosis drugs—Kaftrio/Trikafta, Symkevi and Orkambi—will now be available through England’s National Health Service, following the signing of a long-term reimbursement agreement.
June 21, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
Madrigal Pharmaceuticals, Inc. today announced the publication of the pivotal Phase 3 MAESTRO-NASH trial of resmetirom in the New England Journal of Medicine.
February 8, 2024
·
12 min read
1 of 76,692
Next
